# ATC code L04

ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup L04 is part of the anatomical group L Antineoplastic and immunomodulating agents.
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL04. National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

## L04A Immunosuppressants
### L04AA Selective immunosuppressants

    L04AA03 Antilymphocyte immunoglobulin (horse)
    L04AA04 Antithymocyte immunoglobulin (rabbit)
    L04AA06 Mycophenolic acid
    L04AA15 Alefacept
    L04AA19 Gusperimus
    L04AA22 Abetimus
    L04AA24 Abatacept
    L04AA28 Belatacept
    L04AA32 Apremilast
    L04AA40 Cladribine
    L04AA41 Imlifidase
    L04AA48 Belumosudil
    L04AA58 Efgartigimod alfa
    L04AA60 Remibrutinib

### L04AB Tumor necrosis factor alpha (TNF-α) inhibitors

    L04AB01 Etanercept
    L04AB02 Infliximab
    L04AB03 Afelimomab
    L04AB04 Adalimumab
    L04AB05 Certolizumab pegol
    L04AB06 Golimumab
    L04AB07 Opinercept

### L04AC Interleukin inhibitors

    L04AC01 Daclizumab
    L04AC02 Basiliximab
    L04AC03 Anakinra
    L04AC04 Rilonacept
    L04AC05 Ustekinumab
    L04AC07 Tocilizumab
    L04AC08 Canakinumab
    L04AC09 Briakinumab
    L04AC10 Secukinumab
    L04AC11 Siltuximab
    L04AC12 Brodalumab
    L04AC13 Ixekizumab
    L04AC14 Sarilumab
    L04AC15 Sirukumab
    L04AC16 Guselkumab
    L04AC17 Tildrakizumab
    L04AC18 Risankizumab
    L04AC19 Satralizumab
    L04AC20 Netakimab
    L04AC21 Bimekizumab
    L04AC22 Spesolimab
    L04AC23 Olokizumab
    L04AC26 Goflikicept

### L04AD Calcineurin inhibitors

    L04AD01 Ciclosporin
    L04AD02 Tacrolimus
    L04AD03 Voclosporin

### L04AE Sphingosine 1-phosphate (S1P) receptor modulators

    L04AE01 Fingolimod
    L04AE02 Ozanimod
    L04AE03 Siponimod
    L04AE04 Ponesimod
    L04AE05 Etrasimod

### L04AF Janus-associated kinase (JAK) inhibitors

    L04AF01 Tofacitinib
    L04AF02 Baricitinib
    L04AF03 Upadacitinib
    L04AF04 Filgotinib
    L04AF05 Itacitinib
    L04AF06 Peficitinib
    L04AF07 Deucravacitinib
    L04AF08 Ritlecitinib

### L04AG Monoclonal antibodies

    L04AG01 Muromonab-CD3
    L04AG02 Efalizumab
    L04AG03 Natalizumab
    L04AG04 Belimumab
    L04AG05 Vedolizumab
    L04AG06 Alemtuzumab
    L04AG07 Begelomab
    L04AG08 Ocrelizumab
    L04AG09 Emapalumab
    L04AG10 Inebilizumab
    L04AG11 Anifrolumab
    L04AG12 Ofatumumab
    L04AG13 Teprotumumab
    L04AG14 Ublituximab
    L04AG15 Divozilimab
    L04AG16 Rozanolixizumab
    L04AG17 Seniprutug

### L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors

    L04AH01 Sirolimus
    L04AH02 Everolimus

### L04AJ Complement inhibitors

    L04AJ01 Eculizumab
    L04AJ02 Ravulizumab
    L04AJ03 Pegcetacoplan
    L04AJ04 Sutimlimab
    L04AJ05 Avacopan
    L04AJ06 Zilucoplan
    L04AJ07 Crovalimab
    L04AJ08 Iptacopan
    L04AJ09 Danicopan
    L04AJ10 Vilobelimab
    L04AJ11 Pozelimab

### L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

    L04AK01 Leflunomide
    L04AK02 Teriflunomide

### L04AX Other immunosuppressants

    L04AX01 Azathioprine
    L04AX02 Thalidomide
    L04AX03 Methotrexate
    L04AX04 Lenalidomide
    L04AX05 Pirfenidone
    L04AX06 Pomalidomide
    L04AX07 Dimethyl fumarate
    L04AX08 Darvadstrocel
    L04AX09 Diroximel fumarate
    L04AX10 Tegomil fumarate